Search

Your search keyword '"Fong, Chun Y."' showing total 16 results
Start Over Author "Fong, Chun Y."
16 results on '"Fong, Chun Y."'

1. Experience of the first adult-focussed undiagnosed disease program in Australia (AHA-UDP): solving rare and puzzling genetic disorders is ageless

Author

Wallis, Mathew, Bodek, Simon D., Munro, Jacob, Rafehi, Haloom, Bennett, Mark F., Ye, Zimeng, Schneider, Amy, Gardiner, Fiona, Valente, Giulia, Murdoch, Emma, Uebergang, Eloise, Hunter, Jacquie, Stutterd, Chloe, Huq, Aamira, Salmon, Lucinda, Scheffer, Ingrid, Eratne, Dhamidhu, Meyn, Stephen, Fong, Chun Y., John, Tom, Mullen, Saul, White, Susan M., Brown, Natasha J., McGillivray, George, Chen, Jesse, Richmond, Chris, Hughes, Andrew, Krzesinski, Emma, Fennell, Andrew, Chambers, Brian, Santoreneos, Renee, Le Fevre, Anna, Hildebrand, Michael S., Bahlo, Melanie, Christodoulou, John, Delatycki, Martin, and Berkovic, Samuel F.

Published
2024
Full Text
View/download PDF

3. Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)

Author

Tiong, Ing Soo, primary, Hiwase, Devendra K., additional, Abro, Emad, additional, Bajel, Ashish, additional, Palfreyman, Emma, additional, Beligaswatte, Ashanka, additional, Reynolds, John, additional, Anstee, Natasha, additional, Nguyen, Tamia, additional, Loo, Sun, additional, Chua, Chong Chyn, additional, Ashby, Michael, additional, Wiltshire, Kaitlyn M., additional, Fleming, Shaun, additional, Fong, Chun Y., additional, Teh, Tse-Chieh, additional, Blombery, Piers, additional, Dillon, Richard, additional, Ivey, Adam, additional, and Wei, Andrew H., additional

Published
2024
Full Text
View/download PDF

4. Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients

Author

Thomson, Ashlee J., primary, Rehn, Jacqueline A., additional, Heatley, Susan L., additional, Eadie, Laura N., additional, Page, Elyse C., additional, Schutz, Caitlin, additional, McClure, Barbara J., additional, Sutton, Rosemary, additional, Dalla-Pozza, Luciano, additional, Moore, Andrew S., additional, Greenwood, Matthew, additional, Kotecha, Rishi S., additional, Fong, Chun Y., additional, Yong, Agnes S. M., additional, Yeung, David T., additional, Breen, James, additional, and White, Deborah L., additional

Published
2023
Full Text
View/download PDF

9. Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy

Author

Othman, Jad, Tiong, Ing S., O'Nions, Jenny, Dennis, Mike, Mokretar, Katya, Ivey, Adam, Austin, Michael, Latif, Anne-Louise, Amer, Mariam, Chan, Wei Yee, Crawley, Charles, Crolla, Francesca, Cross, Joe, Dang, Ray, Elliot, Johnathon, Fong, Chun Y., Galli, Sofia, Gallipoli, Paolo, Hogan, Francesca, Kalkur, Pallavi, Khan, Anjum, Krishnamurthy, Pramila, Laurie, John, Loo, Sun, Marshall, Scott, Mehta, Priyanka, Murthy, Vidhya, Nagumantry, Sateesh, Pillai, Srinivas, Potter, Nicola, Sellar, Rob, Taylor, Tom, Zhao, Rui, Russell, Nigel H., Wei, Andrew H., and Dillon, Richard

Abstract

•NPM1MRD by qRT-PCR provides valuable prognostic information in patients with AML treated with venetoclax combinations.•Achievement of MRD negativity in the first 4 cycles identifies a group of patients with good outcomes.

Published
2024
Full Text
View/download PDF

10. Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy

Author

Othman, Jad, Tiong, Ing S., O'Nions, Jenny, Dennis, Mike, Mokretar, Katya, Ivey, Adam, Austin, Michael, Latif, Anne-Louise, Amer, Mariam, Chan, Wei Yee, Crawley, Charles, Crolla, Francesca, Cross, Joe, Dang, Ray, Elliot, Johnathon, Fong, Chun Y., Galli, Sofia, Gallipoli, Paolo, Hogan, Francesca, Kalkur, Pallavi, Khan, Anjum, Krishnamurthy, Pramila, Laurie, John, Loo, Sun, Marshall, Scott, Mehta, Priyanka, Murthy, Vidhya, Nagumantry, Sateesh, Pillai, Srinivas, Potter, Nicola, Sellar, Rob, Taylor, Tom, Zhao, Rui, Russell, Nigel H., Wei, Andrew H., and Dillon, Richard

Published
2023
Full Text
View/download PDF

12. Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals

Author

Chua, Chong C., primary, Grigg, Andrew, additional, Singh, Jasmine, additional, Droogleever, Mark P., additional, Zhang, Lan, additional, Lim, Andrew, additional, Fong, Chun Y., additional, Ting, Stephen B., additional, Schwarer, Anthony, additional, Tiong, Ing S., additional, and Wei, Andrew H., additional

Published
2019
Full Text
View/download PDF

13. Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals.

Author

Chua, Chong C., Grigg, Andrew, Singh, Jasmine, Droogleever, Mark P., Zhang, Lan, Lim, Andrew, Fong, Chun Y., Ting, Stephen B., Schwarer, Anthony, Tiong, Ing S., and Wei, Andrew H.

Subjects
ACUTE myeloid leukemia, TREATMENT effectiveness, REGULATORY approval, COMBINATION drug therapy, TRIAL practice
Abstract

Recent regulatory approval of midostaurin, a FLT3 targeting small molecular inhibitor, will likely lead to increased use of midostaurin in combination with intensive chemotherapy for patients with FLT3-mutant AML. Translation of clinical trial results into everyday practice has its challenges. This study compared the relevance of the trial population and practices studied in the midostaurin registration study (RATIFY) with real-world practice in terms of patient factors, chemotherapy, mutation-specific frequencies and clinical outcomes among patients with FLT3-mutant AML in the pre-midostaurin era (2010–2015) in Australia. We observed substantial diversity of chemotherapy regimens used in the community and limitations of the generalizability of eligibility criteria used in RATIFY (such as age and hyperleukocytosis). This study provides real-world historical data that may be used for comparison with future trial cohorts incorporating FLT3 inhibitors into the management of FLT3-mutant AML and highlights the inherent difficulties in translating clinical trial data into routine practice. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

14. Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse

Author

Lim, Andrew B. M., primary, Curley, Cameron, additional, Fong, Chun Y., additional, Bilmon, Ian, additional, Beligaswatte, Ashanka, additional, Purtill, Duncan, additional, Getta, Bartlomiej, additional, Johnston, Anne M., additional, Armytage, Tasman, additional, Collins, Marnie, additional, Mason, Kate, additional, Fielding, Katherine, additional, Greenwood, Matthew, additional, Gibson, John, additional, Hertzberg, Mark, additional, Wright, Matthew, additional, Lewis, Ian, additional, Moore, John, additional, Curtis, David, additional, Szer, Jeff, additional, Kennedy, Glen, additional, and Ritchie, David, additional

Published
2018
Full Text
View/download PDF

15. Pre-transplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia

Author

Loo, Sun, Potter, Nicola, Ivey, Adam, O’Nions, Jenny, Moon, Roderick, Jovanovic, Jelena, Fong, Chun Y., Anstee, Natasha S., Tiong, Ing Soo, Othman, Jad, Chua, Chong Chyn, Renshaw, Hannah, Baker, Robert, Fleming, Shaun, Russell, Nigel H., Ritchie, David, Bajel, Ashish, Hou, Hsin-An, Dillon, Richard, and Wei, Andrew H.

Abstract

Pre-transplant detection of KMT2Ar MRD ≥0.001% by quantitative PCR was associated with significantly inferior post-transplant survival (2-year RFS 17% vs 59%; p=0.001) and increased cumulative incidence of relapse (2-year CIR 75% vs 25%, p=0.0004).

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results